Historical record - last NADAC effective date: 6/21/2023
Product Information
HYDROCORTISONE VAL 0.2% OINTMT is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $2.2065 per GM under NDC 68462083647. Its NADAC has been published 178 times since Apr 3, 2019.
FDA first approved this application on Dec 14, 2018.
The High Outlier badge above means this manufacturer's average price in the HYDROCORTISONE VALERATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2 mg/g
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462083647
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
6/21/2023
Active Ingredients
HYDROCORTISONE VALERATEApproval Type
Generic (ANDA)
FDA Application
ANDA211750FDA Approved
12/14/2018
On Market Since
3/5/2019
Pharmacological Classes
Price Statistics
The NADAC for HYDROCORTISONE VAL 0.2% OINTMT has been published 178 times since Apr 3, 2019, and over the history we have for it it has declined 24.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2065 per GM |
|---|---|
| All-time high | $2.9036 (Oct 16, 2019) |
| All-time low | $1.6539 (May 17, 2023) |
| Median price | $2.3952 |
| Average price | $2.4806 |
| Largest weekly change | +33.4% (Jun 21, 2023) |
| Weeks tracked | 178 |
| Tracking since | Apr 3, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
0.0%
5Y
-19.4%
All
-24.0%
Last surveyed Feb 21, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
HYDROCORTISONE VALERATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROCORTISONE VAL 0.2% OINTMT?
The current National Average Drug Acquisition Cost (NADAC) for HYDROCORTISONE VAL 0.2% OINTMT, manufactured by Glenmark Pharmaceuticals Inc., USA, is $2.2065 per GM (NDC 68462083647), effective Feb 21, 2024.
How has the price of HYDROCORTISONE VAL 0.2% OINTMT changed over time?
Over the history we have for it, the NADAC for HYDROCORTISONE VAL 0.2% OINTMT has declined 24.0%. It has been tracked across 178 weekly CMS publications since Apr 3, 2019.
What are the highest and lowest recorded NADAC prices for HYDROCORTISONE VAL 0.2% OINTMT?
Since Apr 3, 2019, the NADAC for HYDROCORTISONE VAL 0.2% OINTMT has ranged from a low of $1.6539 (May 17, 2023) to a high of $2.9036 (Oct 16, 2019), with a median of $2.3952 per GM.
Are there cheaper alternatives to HYDROCORTISONE VAL 0.2% OINTMT?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as HYDROCORTISONE VAL 0.2% OINTMT in a comparable dosage form, but none are currently priced below it.
Who manufactures HYDROCORTISONE VAL 0.2% OINTMT?
HYDROCORTISONE VAL 0.2% OINTMT (NDC 68462083647) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.